Dr. Louis Staudt. Dr. Staudt of the National Cancer Institute discusses precision medicine in cancer and the goal of saving lives by getting the right drug to the right patient, at the right time. He explains the comprehensive approach that is key to the successful use of targeted therapies in cancer.
Dr. Staudt discusses his work developing new therapies for the most aggressive and common type of non-Hodgkin lymphoma, known as diffuse large B cell lymphoma (DLBCL). He describes the research that led to a national clinical trial of a targeted therapy—ibrutinib—in patients with DLBCL whose tumors were relapsed or refractory to treatment, the positive outcomes from that trial, and the potential for ibrutinib to be effective in other types of lymphoma.
Dr. Staudt also provides examples from his work that represent recent success stories in other forms of lymphoma and as well as other cancer types.
